Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05041257 · ClinicalTrials.gov registry record · Phase 2
Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT05041257 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 79 participants.
The verdict
NCT05041257, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
PICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Interventions
- DRUG Mirvetuximab soravtansine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2021-10-19 |
| Est. Completion | 2024-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05041257
The ClinicalTrials.gov registry entry for NCT05041257 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mirvetuximab soravtansine is the first listed.
NCT05041257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05041257 about?
NCT05041257 is a clinical study titled "Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers". PICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
What is the current status of trial NCT05041257?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2021-10-19. Estimated completion is 2024-12-12.
What interventions are being tested in trial NCT05041257?
The interventions under investigation include: Mirvetuximab soravtansine (DRUG).
Who is sponsoring clinical trial NCT05041257?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.